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Review Article
HTLV-1 and Adult T-Cell Leukemia: Insights into
Viral Transformation of Cells 30 Years After Virus
Discovery
Kuan-Teh Jeang*
Human T-cell leukemia virus type 1 (HTLV-1), the etiological agent of adult T-cell leukemia, was the first
human retrovirus to be isolated. It is now the 30th anniversary of the initial discovery of HTLV-1. This 
review discusses recent insights into the role of the HTLV-1 Tax oncoprotein in cellular proliferation and
the abrogation of cellular checkpoints that lead to disease progression.
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Human Viruses and Cancer
There are several human viruses that are associ-
ated with cancer. Hepatitis B and C viruses are 
associated with hepatocellular cancer, human
papillomavirus with cervical cancer, Epstein Barr
virus with Burkitt’s lymphoma and nasal pharyn-
geal cancer, Kaposi’s sarcoma herpesvirus with
Kaposi’s sarcoma, and human T-cell leukemia
virus (HTLV-1) with adult T-cell leukemia (ATL).
Of these, HTLV-1 is the only known retrovirus
that has been directly linked to a human cancer.
HTLV-1 was first isolated in 1980 by American sci-
entists,1 followed by contributions from Japanese
colleagues.2 The history of virus discovery and the
original descriptions of adult T-cell leukemia have
been reviewed well elsewhere.3–5 Currently, HTLV-1
infects approximately 20 million individuals
worldwide.6 This year marks the 30th anniversary
of the isolation of HTLV-1, and it is therefore fit-
ting to briefly review the lessons learned from
HTLV-1 about how viruses transform human
cells. HTLV-1 is also associated with an inflamma-
tory disorder called HTLV-associated myelopathy/
tropical spastic paraparesis. This association has
been recently reviewed elsewhere7 and will not
be covered in this mini-review.
Positive Proliferative Factors Needed to
Transform Cells
It has been proposed that there are six hallmarks of
a transformed cell.8 To achieve in vivo tumorigenic-
ity, transformed cells should: (1) be self-sufficient
in terms of growth signals; (2) be insensitive to
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antigrowth signals; (3) evade apoptosis; (4) have
limitless replicative potential; (5) be able to sus-
tain angiogenesis; and (6) be capable of tissue in-
vasion and metastasis.8 To simplify matters,
some of these hallmarks could be grouped to-
gether as factors that are activated during transfor-
mation and endow cells with greater proliferation
and survival potential.
From the perspective of a transforming virus,
the fundamental question is how to increase the
proliferative fitness of the infected cell. HTLV-1 en-
codes the viral Tax oncoprotein whose expression
confers pro-survival and pro-proliferative proper-
ties on cells.9–11 Tax activity is regulated by phos-
phorylation, ubiquitination, and acetylation,12–17
and a number of studies have shown that singular
expression of Tax is sufficient to transform human
T cells.18,19 Transgenic mouse models in which Tax
is the only expressed viral protein confirm its suf-
ficiency for in vivo tumorigensis.20–22 Intriguingly,
recent data suggest that in vivo tumorigenesis
caused by Tax correlates with its propensity to
trigger tissue inflammation.23,24 Collectively, the
extant data are fully consistent with findings from
infected human individuals that Tax expression
selects for increased in vivo cycling of T cells.25
There is a wealth of detail about how Tax pro-
motes cell growth. Early observations suggested
that HTLV-1 infection through the viral Tax pro-
tein induces the expression of IL-2 and the IL-2-
receptor in T cells,26–28 thereby promoting growth
factor-dependent cell proliferation. However, there
is good evidence that, during the later stages of
ATL, IL-2 and IL-2-receptor independent leukemic
cell growth occurs.29 Nevertheless, once inside cells,
Tax is able to activate the cyclic AMP-responsive
binding protein (CREB),30,31 nuclear factor kappa-
B (NF-κB),32–36 cyclin-dependant kinases37,38 and
Akt39 pathways. Part of the ability of Tax to acti-
vate pleiotropic pathways appears to emerge from
its ability to interact with a myriad of host cell
proteins through protein-protein contacts.40,41 The
activation of CREB and NF-κB by Tax requires
different protein domains,42 and their respective
activation has been suggested to be important 
in cellular transformation.18,19,43 Tax-mediated
activation of cyclin-dependant kinases and the pro-
liferative Akt pathway also contribute to growth
dysregulation and transformation.44–48 In addition
to these major routes, cDNA microarray studies
show that many additional cellular genes are ac-
tivated by Tax.49 Hence, it is likely that other
functions/pathways (e.g. JNK1) also contribute
to both general and cell-specific effects of virus-
mediated proliferative dysregulation.50
Abrogation of Checks Against
Proliferation in Tax-Expressing Cells
A seemingly confusing puzzle in cancer biology
arises from the many examples in the literature
of oncoproteins that elicit cellular proliferation or
oncoproteins that elicit cellular apoptosis/senes-
cence.51–53 At face value, these findings are seem-
ingly contradictory. Regarding HTLV-1, there is
disagreement in the literature about whether Tax
accelerates cell cycling or triggers apoptosis/senes-
cence.54–58 So how does one reconcile these op-
posing results? One view is to consider that the
fundamental signal triggered by an oncogene (i.e.
Tax) drives cells to proliferate. In rich medium
and under favorable growth conditions, cells re-
spond appropriately to proliferative signals devel-
oping, over time, a rapidly dividing immortalized
phenotype. Under austere conditions, where the
cell is commanded by the oncogene to grow, but
there are insufficient nutrients available to support
growth, the outcome is that those cells forced to
do what they cannot do are, instead, pushed to
“commit suicide” or become senescent. Hence,
readouts of proliferation, apoptosis or senescence
depend on both the oncogene and the cellular
context in which the oncogene is expressed. The
primary impetus induced by Tax is to cause cells
to accelerate their growth; whether this is the final
outcome is dictated by the cellular setting in which
Tax is expressed.
Clearly then, cellular transformation requires
more than just an increased drive exerted by an on-
coprotein towards cellular proliferation and sur-
vival. This is because cells have evolved checkpoints
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that normally prevent dysregulated growth. Suc-
cessful transformation cannot ensue unless a trans-
forming virus also defeats these multiple censoring
checkpoints within the cells. Studies on HTLV-1
illustrate how the virus disables p53,59–63 Rb,38,64
the DNA damage-sensing Chk1 and Chk2 ki-
nases,17 and the aneuploidy-monitoring spindle
assembly checkpoint.65–67 Currently, the mol-
ecular mechanisms employed by Tax to inacti-
vate these checkpoint proteins require further
investigation. For example, the question of how
Tax disables p53 function remains unresolved.68
Nonetheless, the net outcome of abrogating these
biological checkpoints is the production of a ge-
netically altered cell containing both clastogenic
and aneuploidogenic chromosomal changes.69–72
Arguably, this genetic damage, which occurs as a
consequence of infection by a transforming virus,
most likely explains some of the progress towards
cellular transformation.
Concluding Remarks and Future
Perspectives
The 30th anniversary of the discovery of an im-
portant virus represents an important landmark.
However, paraphrasing the words of Winston
Churchill: “this is not the end, not even the be-
ginning of the end, but it might perhaps be the
end of the beginning”. What then, are the future
questions that need further exploration? First, we
should better understand the factors that are
needed for the initiation of ATL versus those that
are needed for maintenance of the transformed
phenotype. While Tax is required to initiate trans-
formation, this viral oncoprotein is no longer ex-
pressed in many ATL cells.73,74 Thus, it may be
that initial ATL transformation differs from long-
term ATL maintenance in viral (e.g. HBZ)74–76
and/or cellular (e.g. microRNA)77–80 characteris-
tics (Figure). Second, the origin of the cell that is
transformed into an ATL cell by HTLV-1 remains
unclear. Is it a mature CD4+ T cell, or is it a more
primitive hematopoietic stem cell?81 Third, we
still do not fully understand how the HTLV-1 Tax
oncoprotein mediates direct DNA damage. Recent
evidence suggests that this may occur through
Tax-induced reactive oxygen species.82 Whether re-
active oxygen species result from increased cellular
proliferation caused by Tax, or through the ac-
tions of oxidative enzymes induced by Tax, needs
clarification. We look forward to informative an-
swers to these questions in the next 30 years.
CD4+ cell
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Virus
Apoptosis & senescence
Immortalization &
clonal expansion
Transformation
Tax HBZ
microRNAs
Figure. Schematic representation of the steps involved in the HTLV-1-mediated transformation of cells. Transformation is
thought to include the initiation and maintenance of dysregulated growth phenotypes. The initiation of ATL requires viral in-
fection and Tax protein expression. Some cells become immortalized, while others may experience apoptosis and/or senes-
cence. A current hypothesis suggests that the maintenance of ATL may not require Tax expression, but may require the
expression of the viral HBZ protein and/or changes in cellular microRNAs. As discussed in the text, Tax expression can induce
cellular proliferation/immortalization under robust conditions, but when cells encounter austere growth conditions, they
may transit to apoptosis/senescence. HTLV-1 = human T-cell leukemia virus type-1; ATL = adult T-cell leukemia.
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